DTIL - PRECISION BIOSCIENCES INC

QQQ $ 604.92 $ 3.94 (0.66 %)

DIA $ 461.73 $ 2.22 (0.48 %)

SPY $ 665.28 $ 3.75 (0.57 %)

TLT $ 91.09 $ -0.14 (-0.15 %)

GLD $ 391.28 $ -7.46 (-1.88 %)

Previous Close

$ 6.9

Open

$ 6.56

Bid

$ 6.04 x 3

Ask

$ 7.25 x 200

Day's Range

$ 6.40 - $ 7.02

52 Week Range

$ 3.61 - $ 9.20

Volume

417,892

Average Volume

Market Cap

81.33M

Beta (5Y Monthly)

$ 1.47

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2025	06-30-2025	10-Q
2	05-15-2025	03-31-2025	10-Q
3	03-26-2025	12-31-2024	10-K
4	11-04-2024	09-30-2024	10-Q
5	08-01-2024	06-30-2024	10-Q
6	05-13-2024	03-31-2024	10-Q
7	03-27-2024	12-31-2023	10-K
8	11-07-2023	09-30-2023	10-Q
9	08-04-2023	06-30-2023	10-Q
10	05-09-2023	03-31-2023	10-Q
11	03-09-2023	12-31-2022	10-K
12	11-08-2022	09-30-2022	10-Q
13	08-08-2022	06-30-2022	10-Q
14	05-09-2022	03-31-2022	10-Q
15	03-15-2022	12-31-2021	10-K
16	11-10-2021	09-30-2021	10-Q
17	08-12-2021	06-30-2021	10-Q
18	05-13-2021	03-31-2021	10-Q
19	03-18-2021	12-31-2020	10-K
20	11-10-2020	09-30-2020	10-Q
21	08-13-2020	06-30-2020	10-Q
22	05-15-2020	03-31-2020	10-Q
23	03-10-2020	12-31-2019	10-K
24	11-12-2019	09-30-2019	10-Q
25	08-14-2019	06-30-2019	10-Q
26	04-29-2019	03-31-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Precision BioSciences To Present New PBGEN...
10/14/2025 11:08:15

Precision Biosciences Announced The Public...
10/09/2025 11:20:26

Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene ins...

Precision BioSciences Opens First U.S. ELI...
10/07/2025 11:16:03

Massachusetts General Hospital, Harvard Medical School, actively recruiting chronic hepatitis B patients along with multiple gl...

iECURE To Present OTC-HOPE Clinical Trial ...
10/02/2025 12:08:02

Precision BioSciences Announces Late-Break...
09/30/2025 11:06:08

- Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchen...

Precision BioSciences Presents Clinical Da...
09/12/2025 11:02:42

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platfor...

Precision Biosciences To Be Issued Us Pate...
09/08/2025 11:10:39

Strengthens the Company's intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection i...

iECURE Announces It Will Present Additiona...
08/25/2025 12:09:22

iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies...

Precision BioSciences Q2 EPS $(2.13) Misse...
08/07/2025 11:03:33

Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate ...

Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

Precision BioSciences Announces Phase 1 EL...
08/06/2025 11:16:50

Precision BioSciences Says FDA Grants Orph...
07/23/2025 11:03:09

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platfor...

Precision BioSciences Gets FDA Orphan Drug...
07/17/2025 15:52:11

https://t.co/eGDeZfYDhp

Precision Biosciences Announced dditional ...
07/16/2025 11:05:24

New preclinical data for the PBGENE-DMD final clinical candidate demonstrates an increase in dystrophin positive muscle cells a...

12 Health Care Stocks Moving In Wednesday'...
06/25/2025 12:09:37

Market-Moving News for June 25th
06/25/2025 11:17:32

QS: 42% | QuantumScape Achieves Key 2025 Milestone In The Scale-Up Of Its Production Capabilities With The Successful Integrati...

Precision BioSciences Receives FDA Rare Pe...
06/25/2025 11:02:14

HC Wainwright & Co. Reiterates Buy on Prec...
05/21/2025 10:56:30

HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60...

Precision BioSciences Q1 EPS $(2.21) Misse...
05/15/2025 11:03:48

Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate ...

Earnings Scheduled For May 15, 2025
05/15/2025 08:32:23